NANOSTRING TECHNOLOGIES INC (NSTG) Fundamental Analysis & Valuation

NASDAQ:NSTG • US63009R1095

Current stock price

0.1053 USD
-0.06 (-37.43%)
At close:
0.1051 USD
0 (-0.19%)
After Hours:

This NSTG fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. NSTG Profitability Analysis

1.1 Basic Checks

  • In the past year NSTG has reported negative net income.
  • In the past year NSTG has reported a negative cash flow from operations.
NSTG Yearly Net Income VS EBIT VS OCF VS FCFNSTG Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 -50M -100M -150M

1.2 Ratios

  • NSTG has a worse Return On Assets (-60.59%) than 91.80% of its industry peers.
Industry RankSector Rank
ROA -60.59%
ROE N/A
ROIC N/A
ROA(3y)-29.8%
ROA(5y)-31.5%
ROE(3y)-149.76%
ROE(5y)-139.62%
ROIC(3y)N/A
ROIC(5y)N/A
NSTG Yearly ROA, ROE, ROICNSTG Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 -100 -200 -300

1.3 Margins

  • NSTG has a worse Gross Margin (35.72%) than 62.30% of its industry peers.
  • NSTG's Gross Margin has declined in the last couple of years.
  • The Profit Margin and Operating Margin are not available for NSTG so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 35.72%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-9.22%
GM growth 5Y-7.64%
NSTG Yearly Profit, Operating, Gross MarginsNSTG Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 0 50 -50 -100

2

2. NSTG Health Analysis

2.1 Basic Checks

  • NSTG does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, NSTG has more shares outstanding
  • The debt/assets ratio for NSTG is higher compared to a year ago.
NSTG Yearly Shares OutstandingNSTG Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 10M 20M 30M 40M
NSTG Yearly Total Debt VS Total AssetsNSTG Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 100M 200M 300M 400M 500M

2.2 Solvency

  • NSTG has an Altman-Z score of -5.51. This is a bad value and indicates that NSTG is not financially healthy and even has some risk of bankruptcy.
  • The Altman-Z score of NSTG (-5.51) is worse than 81.97% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -5.51
ROIC/WACCN/A
WACC2.41%
NSTG Yearly LT Debt VS Equity VS FCFNSTG Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 0 100M -100M 200M 300M

2.3 Liquidity

  • A Current Ratio of 2.73 indicates that NSTG has no problem at all paying its short term obligations.
  • NSTG has a Current ratio of 2.73. This is comparable to the rest of the industry: NSTG outperforms 52.46% of its industry peers.
  • A Quick Ratio of 2.02 indicates that NSTG has no problem at all paying its short term obligations.
  • NSTG's Quick ratio of 2.02 is in line compared to the rest of the industry. NSTG outperforms 47.54% of its industry peers.
Industry RankSector Rank
Current Ratio 2.73
Quick Ratio 2.02
NSTG Yearly Current Assets VS Current LiabilitesNSTG Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 100M 200M 300M 400M

5

3. NSTG Growth Analysis

3.1 Past

  • The earnings per share for NSTG have decreased strongly by -12.42% in the last year.
  • Looking at the last year, NSTG shows a very strong growth in Revenue. The Revenue has grown by 20.09%.
  • The Revenue has been growing slightly by 2.07% on average over the past years.
EPS 1Y (TTM)-12.42%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%1.27%
Revenue 1Y (TTM)20.09%
Revenue growth 3Y0.45%
Revenue growth 5Y2.07%
Sales Q2Q%62.8%

3.2 Future

  • NSTG is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 15.87% yearly.
  • Based on estimates for the next years, NSTG will show a very strong growth in Revenue. The Revenue will grow by 22.47% on average per year.
EPS Next Y4.9%
EPS Next 2Y22.45%
EPS Next 3Y18.14%
EPS Next 5Y15.87%
Revenue Next Year40.02%
Revenue Next 2Y26.22%
Revenue Next 3Y23.31%
Revenue Next 5Y22.47%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
NSTG Yearly Revenue VS EstimatesNSTG Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 100M 200M 300M 400M 500M
NSTG Yearly EPS VS EstimatesNSTG Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 0 -1 -2 -3

0

4. NSTG Valuation Analysis

4.1 Price/Earnings Ratio

  • NSTG reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year NSTG is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NSTG Price Earnings VS Forward Price EarningsNSTG Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NSTG Per share dataNSTG EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2

4.3 Compensation for Growth

  • NSTG's earnings are expected to grow with 18.14% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y22.45%
EPS Next 3Y18.14%

0

5. NSTG Dividend Analysis

5.1 Amount

  • NSTG does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

NSTG Fundamentals: All Metrics, Ratios and Statistics

NANOSTRING TECHNOLOGIES INC

NASDAQ:NSTG (2/13/2024, 9:56:56 PM)

After market: 0.1051 0 (-0.19%)

0.1053

-0.06 (-37.43%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)11-06
Earnings (Next)02-27
Inst Owners0%
Inst Owner Change-97.01%
Ins Owners17.53%
Ins Owner Change0%
Market Cap5.07M
Revenue(TTM)162.48M
Net Income(TTM)-166.43M
Analysts76.92
Price Target2.07 (1865.81%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-32.73%
Min EPS beat(2)-33.62%
Max EPS beat(2)-31.85%
EPS beat(4)0
Avg EPS beat(4)-36.24%
Min EPS beat(4)-61.05%
Max EPS beat(4)-18.46%
EPS beat(8)0
Avg EPS beat(8)-33.39%
EPS beat(12)0
Avg EPS beat(12)-25.98%
EPS beat(16)1
Avg EPS beat(16)-25.37%
Revenue beat(2)1
Avg Revenue beat(2)0.84%
Min Revenue beat(2)-0.12%
Max Revenue beat(2)1.8%
Revenue beat(4)3
Avg Revenue beat(4)1.93%
Min Revenue beat(4)-0.12%
Max Revenue beat(4)5.95%
Revenue beat(8)4
Avg Revenue beat(8)-2.76%
Revenue beat(12)7
Avg Revenue beat(12)-1.56%
Revenue beat(16)11
Avg Revenue beat(16)2.19%
PT rev (1m)0%
PT rev (3m)-78.95%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-19.5%
EPS NY rev (1m)0%
EPS NY rev (3m)-13.5%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-4.25%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-2.27%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.03
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-3.53
EYN/A
EPS(NY)-1.73
Fwd EYN/A
FCF(TTM)-2.82
FCFYN/A
OCF(TTM)-2.39
OCFYN/A
SpS3.38
BVpS-1.05
TBVpS-1.05
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -60.59%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 35.72%
FCFM N/A
ROA(3y)-29.8%
ROA(5y)-31.5%
ROE(3y)-149.76%
ROE(5y)-139.62%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-9.22%
GM growth 5Y-7.64%
F-Score2
Asset Turnover0.59
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 144.24%
Cap/Sales 12.78%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.73
Quick Ratio 2.02
Altman-Z -5.51
F-Score2
WACC2.41%
ROIC/WACCN/A
Cap/Depr(3y)187.15%
Cap/Depr(5y)166.43%
Cap/Sales(3y)10.15%
Cap/Sales(5y)8.19%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-12.42%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%1.27%
EPS Next Y4.9%
EPS Next 2Y22.45%
EPS Next 3Y18.14%
EPS Next 5Y15.87%
Revenue 1Y (TTM)20.09%
Revenue growth 3Y0.45%
Revenue growth 5Y2.07%
Sales Q2Q%62.8%
Revenue Next Year40.02%
Revenue Next 2Y26.22%
Revenue Next 3Y23.31%
Revenue Next 5Y22.47%
EBIT growth 1Y-18.81%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year34.66%
EBIT Next 3Y23.81%
EBIT Next 5Y19.06%
FCF growth 1Y-50.97%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-37.03%
OCF growth 3YN/A
OCF growth 5YN/A

NANOSTRING TECHNOLOGIES INC / NSTG Fundamental Analysis FAQ

What is the ChartMill fundamental rating of NANOSTRING TECHNOLOGIES INC (NSTG) stock?

ChartMill assigns a fundamental rating of 2 / 10 to NSTG.


Can you provide the valuation status for NANOSTRING TECHNOLOGIES INC?

ChartMill assigns a valuation rating of 0 / 10 to NANOSTRING TECHNOLOGIES INC (NSTG). This can be considered as Overvalued.


Can you provide the profitability details for NANOSTRING TECHNOLOGIES INC?

NANOSTRING TECHNOLOGIES INC (NSTG) has a profitability rating of 0 / 10.


How financially healthy is NANOSTRING TECHNOLOGIES INC?

The financial health rating of NANOSTRING TECHNOLOGIES INC (NSTG) is 2 / 10.


What is the earnings growth outlook for NANOSTRING TECHNOLOGIES INC?

The Earnings per Share (EPS) of NANOSTRING TECHNOLOGIES INC (NSTG) is expected to grow by 4.9% in the next year.